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Ayurveda, the holistic science an upveda of Atharva Veda was incepted 
by Brahma. The aim of Ayurveda is to maintain the state of good health 
of healthy person and render cure to the suffering. A healthy life and 
higher longevity are always desirable. During different stages of human 
life disease prevalence is common due to genetic, infection, 
infestations, systemic, environmental, age related issues and so on. 
Health and disease are two opposite diversions of life. The human body 
is so peculiar, it decays in every moment. As per ayurveda the life span 
(ayu) is devided into three parts viz. Balyavastha, , Maddhyavastha, 
Vriddhavastha
1
. In Vriddhavastha due to Physiological and 
Pathological changes gradual deterioration, decreasing ability and 
inactivity occurs. Ayurveda states that in Vriddhavastha all dhatus 
undergo kshaya leading to Vataprakopa and making individual prone to 
some diseases. Among them Sandhigata vata is very common. 
According to world health organization (WHO) Sandhigata  vata 
(Osteoarthritis) is the second commonest musculoskeletal problem in 
the world population (30%) after back pain (50%). It is occurring in 
about 20% the population as a whole and in 50% of those above the age 
of 60 yrs. Disease starts between the age of 45-50 yrs. It is the common 
cause of disability in an elderly population throughout the world. 
Considering this and keeping in view the prevalence of this disease. I 
have been employed through this Clinical Study. I have done Clinical 
trial work in the management of Sandhigata vata with Ajmodadi Vatak 
(Herbal formulation) and compared with control drug Piroxicam. In 
this study total 80 patients were selected, 50 patients were treated with 
trial drug Ajmodadi Vatak and 30 patients were treated with control 
drug Piroxicam. Study reveals Ajmodadi Vatak is effective in 
Sandhigata Vata. 
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Introduction:- 
Sandhigata vata is the most common disease of old age mentioned under vataroga in ayurveda. Symptomatically 
Sandhigata vata is having close resemblance to osteoarthritis. It occurs due to degeneration of cartilage & synovial 
membrane in joints, which affects mostly weight bearing joints i.e. knees & hips. Common sign & symptoms are 
inflammation & stiffness in joints, pain during movements of joints. Modern science explains it as degenerative joint 
disease. Bone & Joints disorders are curse of the health for human population. Though most of them do not cut the 
years of life but the life of years. Tridosha are the functional integrities of body and their equilibrium keeps the 
person free from ailments and viceversa. Also it is said that disease are caused due to food for the maintenance of 
equilibrium within tridosha conductive food is advocated in Ayurveda. If a person is subjected to vatavardhaka 
ahara it may lead to excitation of vata predominance with the properties of laghu, ruksha, sheeta etc
2
. In Sandhigata 
vata two things happens- Aggravation of vata and dhatukshaya (asthikshaya). As a consequence loss of sheshmaka 
cough occurs. The asthi cartilage undergoes degenerative change putting lipping margins leading to formation of 
osteophytes. Khavaigunya sets in within strotas and in joint cavity through a gradual process. As a result vayu is 
filled in the empty space, vayu being ruksha dries up shleshmaka kapha and other kaphaj elements like snayu, 
kandara making the joint dry and causes sandhigata vata. In the allopathic system of medicine the management 
mainly based on symptomatically relief in painful conditions but still there is need for such therapeutic regimen that 
could retard the disease progression. For the search of such agents herbal remedies and dietary supplements have 
become an important area of research. In this present study and herbal formulation i.e. Ajmodadi vatak mentioned in 
chakradatta has been clinically employed in the treatment of  Sandhigata  vata
3
. 
 
Aims and objective:- 
1. To evaluate efficacy of Ajmodadi Vatak (Trial drug) 
2. To evaluate efficacy of Piroxicam (Control drug) 
3. To compare the efficacy of both drugs (Trial & Control) 
 
Material & Methods:- 
The study has been carried out in department of Kayachikitsa GAM Puri Odisha, total number of 80 cases of either 
sex registered for the study were selected from OPD and IPD. Out of 80 cases, 50 patients were exposed to trial drug 
Ajmodadi vatak and 30 were put under control drug piroxicam. 
 
Inclusion Criteria  
1. A selection criteria was followed on the basis of the classical signs and symptoms and radiological findings 
2. Pain in joints, Swelling, Tenderness, Restricted movement, Stiffness of joints,  Crepitation, Muscular 
Wasting  
3. Patients between age grp of 40-70 years. 
4. Patients without any anatomical deformity of knee.  
 
Exclusion criteria 
1. Patients below 40 and above 70 years of age. 
2. Patients suffering from other diseases like DM, Carcinoma, Tuberculosis, Cardiac disease, Vatarakta etc. 
3. Bed ridden patients. 
4. Patients using active allopathic medicines for pain & inflammation. 
 
Grouping  
Group A 
1. Trial drug - Ajmodadi vatak (Chakradatta Amvatarogadhikar)  
2. Dose - 10 g /day in divided dose 
3. Anupan - Luke warm water 
4. Duration - 35 days 
5. Group B 
6. b) Control drug - Piroxicam 
7. Dose - 20mg OD (after meal) 
8. Duration - 7 days 
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Observation 
Clinical trials were conducted on patients who had been thoroughly scrutinized through clinical signs & symptoms 
& X-ray and diagnosed as Sandhigata vata. Among the trial grp patients, the assessment was carried after each 7 
days interval i.e. (AT1) on 7th day, (AT2) on 14th day, (AT3) on 21st day, (AT4) on 28th day, (AT5) on 35th day, 
Control drug was given for 7 days. Before starting the treatment investigations like Hb, TLC, DLC, ESR, RA, serum 
uric acid were done. After completion of Clinical trial investigations are repeated but no changes were found in their 
measure inspite of having clinical improvement in signs & symptoms of osteoarthritis. Blood count & ESR are 
normal in osteoarthritis
4
. In the present study knee x-ray was done before and after treatment but no changes was 
observed in any X-ray. In this clinical study, maximum 48.75% patients were in 51-60 years of age group, 52.50% 
were females, 99% were married, labour class patients were 38.75%, 27.50% were housewives, vatakapha pre-
dominance was found in 57% Patients, 31% patients had madhyam koshtha. Course of disease was progressive in 
80% patients, 56% of patients were having family history of osteoarthritis, 35% were found in chronic stage , 
38.75% was in menopausal state of life 47.50% patients were obese. Knee is one of the big weight bearing joints and 
thus 97.50% was found knee joint involvement and other joint involved was 2.50%, Consumption of ruksha, sheeta, 
alpa ahara was found in 52.50% patients. Excessive physical exercise was found in 47.50% and excessive fasting 
was found in 20% Patients. 
 
Symptoms wise distribution of 80 Patients of Sandhigata Vata 
     Symptoms Number of Patients Total % 
Trial Group A Control Group B 
Pain 50 30 80 100.00% 
Tenderness 48 30 78 97.50% 
Swelling 50 30 80 100.00% 
Stiffness 49 27 76 95.00% 
Crepitations 43 18 61 76.25% 
Restricted Movements 39 10 49 61.25% 
Muscular Wasting 05 03 08 10.00% 
Radiological Assessment 28 11 39 48.75% 
 
Statistical Analysis showing the effectiveness of Trial and control drug to sign and symptoms 
Sign & 
Symptoms 
Treatment 
Group 
BT & 
AT 
Mean ± SD SEM Df t-value p-value Remarks 
 
 
    
     Pain 
 
 
Ajmodadi 
VaTak 
BT 1.32±.551 .078  
 
 
      50 
   
AT1 1.28±.454 .064 1.429 >0.05 Non Significant 
AT2 1.10±.678 .096 3.718 <0.01 Highly Significant 
AT3 .90±.789 .112 5.957 <0.0001 Extremely 
Significant 
AT4 .54±.676 .096 11.870 <0.0001 Extremely 
Significant 
AT5 .28±.640 .091 13.797 <0.0001 Extremely 
Significant 
 Piroxicam BT 1.17±.461 .084       30    
AT .03±.183 .033 17.954 <0.0001 Extremely 
Significant 
 
 
    
     
Tenderness 
 
 
Ajmodadi 
VaTak 
BT 1.52±.614 .087  
 
       50 
 
   
AT1 1.44±.705 .100 2.064 <0.05 Significant 
AT2 1.38±.667 .094 2.824 <0.01 Highly Significant 
AT3 1.28±.701 .099 3.934 <0.0001 Extremely 
Significant 
AT4 1.10±.707 .100 5.521 <0.0001 Extremely 
Significant 
AT5 1.32±.551 .078 2.646 <0.05 Significant 
 Piroxicam BT 1.23±.430 .079       30    
AT .17±.379 .069 23.028 <0.0001 Extremely 
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Significant 
 
 
    
    Swelling 
 
 
Ajmodadi 
VaTak 
BT 1.48±.677 .096  
 
 
      48 
   
AT1 1.46±.676 .096 1.000 >0.05 Non Significant 
AT2 1.32±.683 .097 3.055 <0.01 Highly Significant 
AT3 1.04±.638 .090 5.755 <0.0001 Extremely 
Significant 
AT4 .82±.629 .089 8.985 <0.0001 Extremely 
Significant 
AT5 .60±.639 .090 9.028 <0.0001 Extremely 
Significant 
 Piroxicam BT 1.20±.484 .088        30    
AT .07±.254 .046 17.954 <0.0001 Extremely 
Significant 
 
 
    
     Stiffness 
 
 
Ajmodadi 
VaTak 
BT 1.58±.538 .076  
 
 
      49 
   
AT1 1.52±.544 .077 1.769 >0.05 Non Significant 
AT2 1.48±.544 .077 2.333 <0.05 Significant 
AT3 1.38±.667 .094 3.500 <0.01 Highly Significant 
AT4 1.32±.713 .101 3.775 <0.001 Extremely 
Significant 
AT5 1.20±.756 .107 5.067 <0.0001 Extremely 
Significant 
 Piroxicam BT 1.13±.571 .104       27    
AT .07±.254 .046 11.217 <0.0001 Extremely 
Significant 
 
 
    
     
Crepitation 
 
 
Ajmodadi 
VaTak 
BT 1.06±0.586 0.083  
 
       43 
  
   
AT1 1.04±0.605 0.086 1.00 >0.05 Non Significant 
AT2 1.04±0.605 0.086 1.00 >0.05 Non Significant 
AT3 1.02±0.622 0.088 1.429 >0.05 Non Significant 
AT4 1.00±0.639 0.090 1.769 >0.05 Non Significant 
AT5 1.00±0.639 0.090 1.769 >0.05 Non Significant 
 Piroxicam BT 0.73±0.691 0.126       18    
AT 0.50±0.572 0.104 2.971 <0.01 Highly Significant 
 
 
    
     Restricted 
Movement 
 
 
Ajmodadi 
VaTak 
BT 0.88±0.558 0.079  
 
      39 
  
   
AT1 0.80±0.571 0.079 2.064 <0.05 Significant 
AT2 0.80±0.571 0.079 2.061 >0.05 Non Significant 
AT3 0.76±0.591 0.084 2.585 <0.05 Non Significant 
AT4 0.76±0.591 0.084 2.585 <0.05 Non Significant 
AT5 0.000 0.000 11.143 <0.0001 Extremely 
Significant 
 Piroxicam BT 0.40±0.621 0.113       10    
AT 0.17±0.379 0.069 2.971 <0.01 Highly Significant 
 
 
    
     Muscular 
Wasting 
 
 
Ajmodadi 
VaTak 
BT 0.14±0.452 0.064  
 
 
      05 
   
AT1 0.14±0.452 0.064 0.000 >0.05 Non Significant 
AT2 0.14±0.452 0.064 0.000 >0.05 Non Significant 
AT3 0.14±0.452 0.064 0.000 >0.05 Non Significant 
AT4 0.14±0.452 0.064 0.000 >0.05 Non Significant 
AT5 0.12±0.435 0.062 1.000 >0.05 Non Significant 
 Piroxicam BT 0.13±0.434 0.079       03    
AT 0.10±0.403 0.074 1.000 >0.05 Non Significant 
 
 
    
Radiological 
 
 
Ajmodadi 
VaTak 
BT 0.60±0.571 0.081     
 
 
      28 
   
AT1 0.60±0.571 0.081 0.000 >0.05 Non Significant 
AT2 0.60±0.571 0.081 0.000 >0.05 Non Significant 
AT3 0.60±0.571 0.081 0.000 >0.05 Non Significant 
AT4 0.58±0.575 0.081 0.573 >0.05 Non Significant 
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AT5 0.54±0.579 0.082 1.353 >0.05 Non Significant 
 Piroxicam BT 0.37±0.49 0.089       11    
AT 0.37±0.49 0.089 0.000 >0.05 Non Significant 
 
Discussion:- 
1. In this study maximum 48.75% patients were in 51-60 years of age grp. Almost all person by age 40 have some 
pathologic change in weight bearing joint. Sandhigata Vata is the Vatavyadhi which mainly occurs in 
vriddhavastha due to aggravation of vata & dhatukshaya. After age 50 which is declining stage of madhyavaya 
symptoms like joint pain & swelling started appearing commonly & it becomes prominent by age 70. 
2. 52.50 % were female patients, which indicates that Sandhigata vata is more common in female and here the lack 
of female hormone (oestrogen) in the menopausal period also plays an important role. Modern thought also 
reflect the same type of prevalence
5
. Also in menopausal state of life due to Dhatukshaya aggravation of vayu 
occurs that causes Sandhigata vata. 
3. 52.50% patients did not have regular exercise in their routine life. Lack of exercise gradually leads to the weight 
gain which exerts pressure on weight bearing joints which ultimately leads to Sandhigata vata. Osteoarthritis 
mainly occurs in the weight bearing joints Data shows 11 pound weight reduction, reduce 50% risk of 
osteoarthritis. 5% weight loss in over weight patients gives 18% gain in overall function
6
. So weight reduction 
is very important in case of osteoarthritis.  
4. Among the other causative factors in 47.50 %, intake of ruksha, sheeta & alpa ahara were also found. These 
nidan played an important role in aggravation of vayu and thus causes Sandhigata vata. 
 
Probable Mechanism of trial drug 
Probable Mechanism of trial drug Ajmodadi vatak is having 6 ingredient cedrus deodara, piper nigrum, embelia 
ribes & anethum sowa which possess anti-inflammatory activity and 4 ingredients piper nigrum, embelia ribes, 
cedrus deodara & zingiber officinale are having analgesic properties. (Maximum ingredients are Kaphavata-
Shamak) which reduces swelling and pacifies pain. The combination of piper longum, piper nigrum and zingiber 
officinal, known in ayurveda as trikatu is a significant bio enhancer. Some ingredients like piper longum, Embelia 
ribes, Plumbego Zeylanica, Argyria speciosa, old jaggery are having rasayana property can delay the further 
degeneration process in Sandhigata Vata. 
 
Ajmodadi vatak is also having properties like ushna, snigdha, Vatashamak which helps in pacification of aggravated 
vata and subsides the pain. On the overall effect of Ajmodadi Vatak is anti inflammatory, analgesic and 
immunomodulatory which reduces inflammation, subside the pain, reduces Stiffness and improves joint mobility 
and help prevent degenerative changes in Sandhi (Joints)
7-14
. 
Total effect of therapy 
              Sr. 
No. 
Clinical 
assessment 
Trial Grp Control 
Grp 
AT1 
(7days) 
AT2 
(14days) 
AT3(21da
ys) 
AT4(28days) AT5(35days
) 
AT(7days) 
F % F % F % F % F % F % 
1 Maximum 
Improvement       
(75-100%) 
- - - - 05 10 08 16 13 26 27 90 
2 Moderate 
Improvement  
(>50 to 75%) 
- - 01 02 03 06 12 24 21 42 03 10 
3 Mild 
Improvement  
(>25 to 50%) 
03 06 14 28 18 36 22 44 12 24 - - 
4 No 
Improvement 
(<25%) 
47 94 35 70 24 48 08 16 04 08 - - 
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Conclusion:- 
Sandhigata Vata is the commonest form of articular disorder which occurs in vriddhavastha which limits everyday 
activities making patients disabled, Vata dosha plays main role. Allopathic treatment has its own limitation in 
managing this disease with troublesome side effects. Whereas such type of condition can be better treatable by the 
management mentioned in Ayurvedic Classics. So this clinical study is carried out with ajmodadi vatak a herbal 
formulation mentioned in Chakradatta as effective in vata vyadhi. In present study data shows that Ajmodadi Vatak 
is an effective remedy in Sandhigata Vata (Osteoarthritis) as it has potent analgesic  & anti inflammatory effects also 
it renders immunomodulatory effects in body which aids in arresting the progress of the disease. In both groups (A 
& B), 26% & 90% patients achieved maximum improvement, 42% & 10% patients were having moderate 
improvement and in grp A 24 patients found in mild improvement. There was no apparent change was observed in 
X-ray before and after treatment. So similar type of assignments should be continued to make use for longer 
duration pinpointing on the radiological progression. Present study reveals that the selected management have 
potential effect on Sandhigata Vata with added advantage of being free from side effects as compared to control 
drug.   
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